Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
Clinical trial NCT05241392 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05241392
- Sponsor
- Beijing Tiantan Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-27
- Primary completion
- 2024-11-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.